Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5186833 | 1.00 | TP53 (0.44) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL5188226 | 1.00 | TP53 (0.44) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL5186842 | 1.00 | TP53 (0.44) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL30018727 | 0.82 | EPHX1 (0.38) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL7110042 | 0.79 | TP53 (0.34) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL5443983 | 0.78 | EPHX1 (0.41) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL5981213 | 0.78 | EPHX1 (0.41) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL9793827 | 0.78 | TP53 (0.41) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL13674295 | 0.78 | TP53 (0.41) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL612202 | 0.78 | TP53 (0.41) | TP53KDM4EGMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389174-B1 | PREPARATION AND USE OF DIOLS | JOHNSON MATTHEY PLC (GB) | 2007-07-11 | — | — | EP | disclosed |
| US-7232933-B2 | Lewis acid-catalysed aldehyde addition reaction on hydroxyalkynes followed by hydrogenation; preparing chiral 1,4-diols suitable for the preparation of chiral phospholane ligands for use in asymmetric catalysis. | JOHNSON MATTHEY PLC (GB) | 2007-06-19 | — | — | US | disclosed |
| US-20040143143-A1 | Lewis acid-catalysed aldehyde addition reaction on hydroxyalkynes followed by hydrogenation; preparing chiral 1,4-diols suitable for the preparation of chiral phospholane ligands for use in asymmetric catalysis. | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2004-07-22 | — | — | US | disclosed |
| EP-1389174-A1 | PREPARATION AND USE OF DIOLS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094741-A1 | PREPARATION AND USE OF DIOLS | JOHNSON MATTHEY PLC (GB) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143143-A1 | Lewis acid-catalysed aldehyde addition reaction on hydroxyalkynes followed by hydrogenation; preparing chiral 1,4-diols suitable for the preparation of chiral phospholane ligands for use in asymmetric catalysis. | ALDH3A1, GNPAT, HACL2 | TP53 4593/4885KDM4E 1924/4885GMNN 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.